- AstraZeneca (NASDAQ:AZN) and Merck's (NYSE:MRK) Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers.
- The three approvals authorize Lynparza for: maintenance treatment after 1st-line chemotherapy containing bevacizumab for patients with ovarian cancer;
- The treatment of patients with BRCA gene-mutated castrate-resistant prostate cancer and;
- As maintenance treatment after platinum-based chemotherapy for patients with pancreas cancer.
- Lynparza is being jointly developed and commercialized by AstraZeneca and Merck, under a global strategic oncology collaboration announced in July 2017.
- https://seekingalpha.com/news/3647466-astrazeneca-merck-s-lynparza-okd-in-japan-for-cancers
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.